Lutz Heinemann

Summary

Publications

  1. ncbi Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    J Diabetes Sci Technol 5:681-6. 2011
  2. ncbi Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes
    Christoph Kapitza
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Care 33:1288-90. 2010
  3. ncbi AP@home: a novel European approach to bring the artificial pancreas home
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    J Diabetes Sci Technol 5:1363-72. 2011
  4. ncbi Continuous glucose monitoring during exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion
    Christoph Kapitza
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    J Diabetes Sci Technol 4:123-31. 2010
  5. ncbi Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    J Diabetes Sci Technol 4:750-3. 2010
  6. ncbi Biosimilar insulins: how similar is similar?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    J Diabetes Sci Technol 5:741-54. 2011
  7. ncbi Lancing: quo vadis?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    J Diabetes Sci Technol 5:966-81. 2011
  8. ncbi Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, GmbH, Neuss, Germany
    J Diabetes Sci Technol 3:1490-500. 2009
  9. ncbi Quality of glucose measurement with blood glucose meters at the point-of-care: relevance of interfering factors
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung GmbH, Hellersbergstrasse 9, Neuss, Germany
    Diabetes Technol Ther 12:847-57. 2010

Detail Information

Publications9

  1. ncbi Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    J Diabetes Sci Technol 5:681-6. 2011
    ..Evaluation of postprandial glycemic excursions in patients with type 1 diabetes with three prandial insulins: VIAject™ (Linjeta™), an ultra-fast insulin (UFI); insulin lispro (LIS); and regular human insulin (RHI)...
  2. ncbi Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes
    Christoph Kapitza
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Diabetes Care 33:1288-90. 2010
    ..To determine the pharmacokinetic and pharmacodynamic properties of an oral insulin (OI) formulation compared with subcutaneously injected regular human insulin (RHI)...
  3. ncbi AP@home: a novel European approach to bring the artificial pancreas home
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    J Diabetes Sci Technol 5:1363-72. 2011
    ....
  4. ncbi Continuous glucose monitoring during exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion
    Christoph Kapitza
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    J Diabetes Sci Technol 4:123-31. 2010
    ..The aim of this study was to assess glucose changes during and after physical exercise in patients with type 1 diabetes managed by continuous subcutaneous insulin infusion before and after a 14-day moderate or intense exercise program...
  5. ncbi Insulin absorption from lipodystrophic areas: a (neglected) source of trouble for insulin therapy?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    J Diabetes Sci Technol 4:750-3. 2010
    ..Nevertheless, it is impressive to see how often metabolic control improves considerably once the patients apply the insulin into other skin areas...
  6. ncbi Biosimilar insulins: how similar is similar?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    J Diabetes Sci Technol 5:741-54. 2011
    ....
  7. ncbi Lancing: quo vadis?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    J Diabetes Sci Technol 5:966-81. 2011
    ..This may have a greater impact on metabolic control than many of the new and expensive antidiabetic drugs...
  8. ncbi Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements?
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung, GmbH, Neuss, Germany
    J Diabetes Sci Technol 3:1490-500. 2009
    ..Therefore, the recommendation made in most of these studies (i.e., use of dual-wave bolus) has to be accepted with care, until we have better evidence...
  9. ncbi Quality of glucose measurement with blood glucose meters at the point-of-care: relevance of interfering factors
    Lutz Heinemann
    Profil Institut für Stoffwechselforschung GmbH, Hellersbergstrasse 9, Neuss, Germany
    Diabetes Technol Ther 12:847-57. 2010
    ..This depends on the application in which meters designed for self-monitoring of BG (SMBG) are used...